entertainment -WSS

entertainment

author：hotspot 2025-10-03 00:07:23 - browse：14532

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Infant mortality in U.S. rose last year for first time in decades: CDC

WSS

Sarepta Duchenne therapy fails to meet primary endpoint in trial

After Sarepta trial failure, Duchenne families brace for more debate

Gene therapy’s promise and the high cost of hope

Medicare must police algorithms in Medicare Advantage, Dems say

Life sciences investors close nearly $6 billion in new funds

Oak trusses raised to roof of fire

knowledge

entertainment

entertainment

How to save PrEP access — and even expand it

NIH fellows want a pay raise. Will that mean less money for grants?

In Memoriam: Notable people who died in 2023

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Activists slam private health insurers over coverage restrictions

Charles Manson follower Leslie Van Houten released from prison after 53 years

DIEP, the 'gold standard' of breast reconstruction, is under threat

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

In age of alternative facts, a scholarly course on calling out crap

Coloradans with cystic fibrosis could lose access to Trikafta

hotspot

HCA discloses massive data breach affecting 11 million patients

Humans aren't the only ones with an imagination. Rats have it too

Study: Pain burden is higher in Black NFL players than white ones

Medicare must police algorithms in Medicare Advantage, Dems say

Palantir health business leans on meeting customers’ needs

What is microchimerism and how does it affect maternal health?

hotspot

leisure time

focus

leisure time